At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.

FDA Commissioner Martin Makary said this move would offer newer treatments for patients quicker, while also reducing the cost of research and development. Other news includes: lab models of pain ...

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

Change does not happen overnight. Democracy does not suddenly collapse. It is a series of restrictive policies and an ...

Gilead Sciences Inc. closed 15.47% short of its 52-week high of $119.96, which the company reached on March 10th.

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.25, marking a +2% move from the previous day. The stock lagged the S&P 500's daily gain of 9.52%. Elsewhere, the Dow saw an upswing ...

Over the last few years, with fears increased in the healthcare industry that its top executives could be targets of violence ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...